VTGN Valuation
Vistagen Therapeutics Inc
$
3.340
- Overview
- Forecast
- Valuation
- Earnings
VTGN Relative Valuation
VTGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VTGN is overvalued; if below, it's undervalued.
Historical Valuation
Vistagen Therapeutics Inc (VTGN) is now in the Fair zone, suggesting that its current forward PS ratio of 281.91 is considered Fairly compared with the five-year average of -3.69. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.32 to 4.39 according to relative valuation methord.
Relative Value
Fair Zone
1.32-4.39
Current Price：3.34
Fair
-2.03
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Vistagen Therapeutics Inc. (VTGN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.56
EV/EBIT
Vistagen Therapeutics Inc. (VTGN) has a current EV/EBIT of -0.56. The 5-year average EV/EBIT is -2.33. The thresholds are as follows: Strongly Undervalued below -9.00, Undervalued between -9.00 and -5.66, Fairly Valued between 1.01 and -5.66, Overvalued between 1.01 and 4.34, and Strongly Overvalued above 4.34. The current Forward EV/EBIT of -0.56 falls within the Historic Trend Line -Fairly Valued range.
281.91
PS
Vistagen Therapeutics Inc. (VTGN) has a current PS of 281.91. The 5-year average PS is 152.00. The thresholds are as follows: Strongly Undervalued below -369.71, Undervalued between -369.71 and -108.85, Fairly Valued between 412.85 and -108.85, Overvalued between 412.85 and 673.71, and Strongly Overvalued above 673.71. The current Forward PS of 281.91 falls within the Historic Trend Line -Fairly Valued range.
-1.32
P/OCF
Vistagen Therapeutics Inc. (VTGN) has a current P/OCF of -1.32. The 5-year average P/OCF is -2.76. The thresholds are as follows: Strongly Undervalued below -9.95, Undervalued between -9.95 and -6.36, Fairly Valued between 0.84 and -6.36, Overvalued between 0.84 and 4.43, and Strongly Overvalued above 4.43. The current Forward P/OCF of -1.32 falls within the Historic Trend Line -Fairly Valued range.
-1.31
P/FCF
Vistagen Therapeutics Inc. (VTGN) has a current P/FCF of -1.31. The 5-year average P/FCF is -1.42. The thresholds are as follows: Strongly Undervalued below -6.01, Undervalued between -6.01 and -3.71, Fairly Valued between 0.88 and -3.71, Overvalued between 0.88 and 3.17, and Strongly Overvalued above 3.17. The current Forward P/FCF of -1.31 falls within the Historic Trend Line -Fairly Valued range.
Vistagen Therapeutics Inc (VTGN) has a current Price-to-Book (P/B) ratio of 1.72. Compared to its 3-year average P/B ratio of 1.49 , the current P/B ratio is approximately 15.26% higher. Relative to its 5-year average P/B ratio of 2.99, the current P/B ratio is about -42.32% higher. Vistagen Therapeutics Inc (VTGN) has a Forward Free Cash Flow (FCF) yield of approximately -49.07%. Compared to its 3-year average FCF yield of -93.78%, the current FCF yield is approximately -47.67% lower. Relative to its 5-year average FCF yield of -63.56% , the current FCF yield is about -22.79% lower.
1.72
P/B
Median3y
1.49
Median5y
2.99
-49.07
FCF Yield
Median3y
-93.78
Median5y
-63.56
Competitors Valuation Multiple
The average P/S ratio for VTGN's competitors is 91.97, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN) exhibits a P/S ratio of 281.91, which is 206.52% above the industry average. Given its robust revenue growth of 190.48%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of VTGN increased by 10.96% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 84.00K to 244.00K.
The secondary factor is the Margin Expansion, contributed -51.58%to the performance.
Overall, the performance of VTGN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Vistagen Therapeutics Inc (VTGN) currently overvalued or undervalued?
Vistagen Therapeutics Inc (VTGN) is now in the Fair zone, suggesting that its current forward PS ratio of 281.91 is considered Fairly compared with the five-year average of -3.69. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.32 to 4.39 according to relative valuation methord.
What is Vistagen Therapeutics Inc (VTGN) fair value?
How does VTGN's valuation metrics compare to the industry average?
What is the current P/B ratio for Vistagen Therapeutics Inc (VTGN) as of Sep 01 2025?
What is the current FCF Yield for Vistagen Therapeutics Inc (VTGN) as of Sep 01 2025?
What is the current Forward P/E ratio for Vistagen Therapeutics Inc (VTGN) as of Sep 01 2025?